Bristol-Myers Squibb Debt to Equity Ratio 2006-2018 | BMY

Current and historical debt to equity ratio values for Bristol-Myers Squibb (BMY) over the last 10 years.
Bristol-Myers Squibb Annual Debt/Equity Ratio
2017 0.67
2016 0.41
2015 0.46
2014 0.52
2013 0.55
2012 0.54
2011 0.35
2010 0.35
2009 0.43
2008 0.55
2007 0.59
2006 0.74
2005 0.77
Bristol-Myers Squibb Quarterly Debt/Equity Ratio
Q2 2018 0.60
Q1 2018 0.60
Q4 2017 0.67
Q3 2017 0.57
Q2 2017 0.55
Q1 2017 0.58
Q4 2016 0.41
Q3 2016 0.43
Q2 2016 0.45
Q1 2016 0.46
Q4 2015 0.46
Q3 2015 0.48
Q2 2015 0.48
Q1 2015 0.48
Q4 2014 0.52
Q3 2014 0.50
Q2 2014 0.50
Q1 2014 0.49
Q4 2013 0.55
Q3 2013 0.49
Q2 2013 0.50
Q1 2013 0.58
Q4 2012 0.54
Q3 2012 0.53
Q2 2012 0.34
Q1 2012 0.33
Q4 2011 0.35
Q3 2011 0.34
Q2 2011 0.34
Q1 2011 0.34
Q4 2010 0.35
Q3 2010 0.42
Q2 2010 0.42
Q1 2010 0.41
Q4 2009 0.43
Q3 2009 0.46
Q2 2009 0.46
Q1 2009 0.51
Q4 2008 0.55
Q3 2008 0.48
Q2 2008 0.73
Q1 2008 0.61
Q4 2007 0.59
Q3 2007 0.55
Q2 2007 0.67
Q1 2007 0.72
Q4 2006 0.74
Q3 2006 0.73
Q2 2006 0.72
Q1 2006 0.74
Q4 2005 0.77
Q3 2005 0.55
Q2 2005 0.58
Q1 2005 0.83
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $96.944B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $350.789B 16.76
Pfizer (PFE) United States $243.651B 14.26
Novartis AG (NVS) Switzerland $190.263B 16.32
Merck (MRK) United States $178.137B 15.73
AbbVie (ABBV) United States $145.067B 14.17
Novo Nordisk (NVO) Denmark $114.528B 18.31
Eli Lilly (LLY) United States $109.815B 20.33
Sanofi (SNY) France $104.261B 13.20
AstraZeneca (AZN) United Kingdom $99.745B 10.97
GlaxoSmithKline (GSK) United Kingdom $99.569B 13.30